Edition:
United Kingdom

People: Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

2.71CAD
13 Sep 2019
Change (% chg)

$-0.08 (-2.87%)
Prev Close
$2.79
Open
$2.80
Day's High
$2.82
Day's Low
$2.66
Volume
38,172
Avg. Vol
94,436
52-wk High
$4.94
52-wk Low
$2.62

Zuerblis, Kenneth 

Mr. Kenneth J. Zuerblis serves as an Independent Director of Resverlogix Corp. Mr. Zuerblis received a BS in Accounting and is a Certified Public Accountant with nearly 30 years of experience, has held senior financial positions with three publicly-traded companies and has held directorships with numerous organizations. Mr. Zuerblis served as Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc. from 2011 to 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Mr. Zuerblis began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis currently serves on the boards of directors (since 2012) of Stemline Therapeutics, Inc. and Zenith Epigenetics Corp. (since 2013).

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --